

A Study of Concurrent Stereotactic Body Radiotherapy With Opdu- lag in Metastatic Uveal Melanoma

NCT05077280

Status	RECRUITING
Phase	Phase 2
Sponsor	California Pacific Medical Center Research Institute
Enrollment	40 participants

Plain Language Summary

This trial is testing a combination of focused radiation (stereotactic body radiotherapy) alongside a newer immunotherapy drug called Opdualag (relatlimab + nivolumab) in people with metastatic uveal melanoma (a rare melanoma that originates in the eye).

****You may be eligible if...****

- You have measurable metastatic uveal melanoma
- Your general health is good (performance status 0–1)
- You are not on other cancer treatments currently
- Your blood counts and organ function are adequate
- You have not previously received Opdualag or relatlimab

****You may NOT be eligible if...****

- More than 50% of your liver is occupied by tumors
- You have active brain metastases
- You are pregnant
- You have active hepatitis B, HIV, or certain autoimmune diseases
- You have had prior liver embolization or radiation
- You are on systemic steroids

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (10)

- measurable metastatic uveal melanoma.
- No concomitant therapy.
- Prior PD1 or tebendafesp allowed.
- Performance status 0-1.
- No active Hepatitis B.
- ... and 5 more (see full listing online)

Exclusion (7)

- Liver tumor volume \geq 50%.
- Active CNS metastases.
- Pregnancy.
- Prior therapy with Opdualag or relatlimab
- Certain autoimmune diseases.

<https://clinicaltrials.gov/study/NCT05077280>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.

Locations (1 total)

California Pacific Medical Center Research Institute, San Francisco, California, United States